WO2003105658A3 - Procedes et systemes de gestion de la maladie d'alzheimer - Google Patents

Procedes et systemes de gestion de la maladie d'alzheimer Download PDF

Info

Publication number
WO2003105658A3
WO2003105658A3 PCT/IL2003/000508 IL0300508W WO03105658A3 WO 2003105658 A3 WO2003105658 A3 WO 2003105658A3 IL 0300508 W IL0300508 W IL 0300508W WO 03105658 A3 WO03105658 A3 WO 03105658A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
systems
methods
alzheimer
managing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2003/000508
Other languages
English (en)
Other versions
WO2003105658A2 (fr
Inventor
Alon Shalev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brainsgate Ltd
Original Assignee
Brainsgate Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/294,310 external-priority patent/US7146209B2/en
Application filed by Brainsgate Ltd filed Critical Brainsgate Ltd
Priority to AU2003241131A priority Critical patent/AU2003241131A1/en
Priority to EP03730451A priority patent/EP1521614A2/fr
Priority to CA002489341A priority patent/CA2489341A1/fr
Publication of WO2003105658A2 publication Critical patent/WO2003105658A2/fr
Publication of WO2003105658A3 publication Critical patent/WO2003105658A3/fr
Priority to US10/952,536 priority patent/US20050159790A1/en
Priority to IL16576404A priority patent/IL165764A0/xx
Anticipated expiration legal-status Critical
Priority to US10/518,322 priority patent/US7640062B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Developmental Disabilities (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur un procédé de traitement de la maladie d'Alzheimer (AD). Ce procédé consiste à stimuler un ganglion sphéno-palatin (SPG) d'un sujet afin de modifier la concentration d'une substance dans le cerveau du sujet.
PCT/IL2003/000508 2000-05-08 2003-06-13 Procedes et systemes de gestion de la maladie d'alzheimer Ceased WO2003105658A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003241131A AU2003241131A1 (en) 2002-06-14 2003-06-13 Methods and systems for management of alzheimer's disease
EP03730451A EP1521614A2 (fr) 2002-06-14 2003-06-13 Procedes et systemes de gestion de la maladie d'alzheimer
CA002489341A CA2489341A1 (fr) 2002-06-14 2003-06-13 Procedes et systemes de gestion de la maladie d'alzheimer
US10/952,536 US20050159790A1 (en) 2000-05-08 2004-09-27 Stimulation for treating and diagnosing conditions
IL16576404A IL165764A0 (en) 2002-06-14 2004-12-14 Methods and systems for managment of Alzheimers disease
US10/518,322 US7640062B2 (en) 2000-05-08 2005-07-08 Methods and systems for management of alzheimer's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38893102P 2002-06-14 2002-06-14
US60/388,931 2002-06-14
US10/294,310 2002-11-14
US10/294,310 US7146209B2 (en) 2000-05-08 2002-11-14 Stimulation for treating eye pathologies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/952,536 Continuation-In-Part US20050159790A1 (en) 2000-05-08 2004-09-27 Stimulation for treating and diagnosing conditions

Publications (2)

Publication Number Publication Date
WO2003105658A2 WO2003105658A2 (fr) 2003-12-24
WO2003105658A3 true WO2003105658A3 (fr) 2004-03-18

Family

ID=29739267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000508 Ceased WO2003105658A2 (fr) 2000-05-08 2003-06-13 Procedes et systemes de gestion de la maladie d'alzheimer

Country Status (4)

Country Link
EP (1) EP1521614A2 (fr)
AU (1) AU2003241131A1 (fr)
CA (1) CA2489341A1 (fr)
WO (1) WO2003105658A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7146209B2 (en) 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7117033B2 (en) * 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
JP4311904B2 (ja) 2000-05-08 2009-08-12 ブレインスゲート リミテッド 血液脳関門及び脳血流の性質を改善するための翼口蓋神経節の刺激方法及び装置
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US7499748B2 (en) 2005-04-11 2009-03-03 Cardiac Pacemakers, Inc. Transvascular neural stimulation device
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US7965180B2 (en) 2006-09-28 2011-06-21 Semiconductor Energy Laboratory Co., Ltd. Wireless sensor device
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US9572695B2 (en) 2009-08-24 2017-02-21 New Phase Ltd Phase-change and shape-change materials
EP3533803B1 (fr) 2010-08-14 2021-10-27 AbbVie Inc. Anticorps anti-bêta-amyloïde
EP2878335B1 (fr) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant et système d'implantation pour stimulateur neural
EP3226819B1 (fr) 2014-11-25 2018-10-24 New Phase Ltd. Nanoparticule à changement de phase
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
US20200113854A1 (en) * 2017-05-30 2020-04-16 Morinaga Milk Industry Co., Ltd. Composition for Improving Brain Function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792100A (en) * 1995-05-19 1998-08-11 Shantha; T. R. Treatment method for transsphenoidal stimulation of the pituitary gland and of nerve structures
US6325475B1 (en) * 1996-09-06 2001-12-04 Microfab Technologies Inc. Devices for presenting airborne materials to the nose
US6338715B1 (en) * 1999-03-31 2002-01-15 Microfab Technologies, Inc. Digital olfactometer and method for testing olfactory thresholds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287793B1 (en) 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792100A (en) * 1995-05-19 1998-08-11 Shantha; T. R. Treatment method for transsphenoidal stimulation of the pituitary gland and of nerve structures
US6325475B1 (en) * 1996-09-06 2001-12-04 Microfab Technologies Inc. Devices for presenting airborne materials to the nose
US6338715B1 (en) * 1999-03-31 2002-01-15 Microfab Technologies, Inc. Digital olfactometer and method for testing olfactory thresholds

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7146209B2 (en) 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
CA2489341A1 (fr) 2003-12-24
AU2003241131A8 (en) 2003-12-31
EP1521614A2 (fr) 2005-04-13
AU2003241131A1 (en) 2003-12-31
WO2003105658A2 (fr) 2003-12-24

Similar Documents

Publication Publication Date Title
WO2003105658A3 (fr) Procedes et systemes de gestion de la maladie d'alzheimer
FR15C0054I2 (fr) Procedes de traitement de la maladie de parkinson
EP1221153A4 (fr) Systeme destine a optimiser des processus neurophysiologiques
BRPI0416361A (pt) métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente
EP1490050A4 (fr) Methodes de traitement de la maladie d'alzheimer et amelioration neuro-cognitive
NO965098L (no) Perfluoralkylketoninhibitorer av elastase og fremgangsmåter for fremstilling av disse
EP1635763A4 (fr) Procede de traitement de maladie neurodegenerative
WO2003103653A8 (fr) Methodes de traitement de la maladie d'alzheimer par des amides d'acide aryl alcanoique
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
EP1721870A4 (fr) Procede de nitrification d'eau contenant de l'ammonium azote et procede de traitement correspondant
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
EP1596868A4 (fr) Methode de traitement d'une insuffisance cardiaque grave et medicament associe
EP4247357A4 (fr) Méthode de traitement de la maladie de parkinson
EP1255556A4 (fr) Utilisations a des fins neuroprotectrices, antithrombotiques et anti-inflammatoires de la proteine c activee
EP1444516A4 (fr) Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
MX2023006598A (es) Biomarcadores agonistas del trem2 y métodos para usarlos.
EP1024697A4 (fr) Methode de traitement de la maladie d'alzheimer
EP1817050A4 (fr) Diagnostic et traitement de la maladie d'alzheimer
EP1855679A4 (fr) Inhibiteurs de la beta-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
EP4091621A4 (fr) Procédé de traitement d'une lésion nerveuse et maladie associée
FR2869602B1 (fr) Procede de traitement electromagnetique de l'eau lui donnant une activite biologique
EP2059235A4 (fr) Méthode de prévention et de traitement de la maladie d'alzheimer
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
EP1924286A4 (fr) Procédé thérapeutique et/ou phropylactique pour le traitement d'une maladie auto-immune
MX2023014113A (es) Biomarcadores agonistas de trem2 y métodos para usarlos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10952536

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2489341

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003730451

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 38/MUMNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2003730451

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006020299

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10518322

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10518322

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP